Kraig Biocraft Laboratories Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced its first sample shipment of recombinant spider silk fibers for biomedical applications, following increased demand over the past two quarters. The company utilizes genetically enhanced silkworms to produce spider silk, combining its properties with established silk supply chains. With enhanced production in Vietnam, Kraig Labs aims to supply R&D samples to the medical community. COO Jon Rice noted rising demand and sees potential for significant growth in the biomedical space, which may require FDA approval for further applications.

Positive

• First shipment of recombinant spider silk fibers indicates strong market demand.
• Utilization of genetically enhanced silkworms could lead to large-scale spider silk production.
• Increased production capabilities in Vietnam position the company for growth in biomedical applications.

Negative

• None.

ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.

Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known cases of sutures made from spider silk date back to the 18^th century, limitations in the production and costs of spider silk have prevented its broad adoption.

Kraig Labs' revolutionary approach, creating recombinant spider silk technology utilizing genetically enhanced silkworms, unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.

With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community's needs. This week's shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.

"Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics," said COO, Jon Rice. "With the great work our team in Vietnam has done, increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the Company's long-term growth. Over the coming months, we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films that we have already developed into the broad field of biomaterials."

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

FAQ

What recent shipment did Kraig Biocraft Laboratories announce on May 17, 2022?

Kraig Biocraft Laboratories announced the shipment of its first recombinant spider silk fibers for biomedical applications.

How does Kraig Labs plan to utilize its spider silk technology?

The company aims to supply spider silk for diverse biomedical applications, including tissue engineering.

What is the significance of the increase in demand for KBLB's products?

The rising demand indicates a growing interest in spider silk for medical applications, potentially leading to long-term market growth.

What is the company's strategy for scaling production?

Kraig Labs is leveraging its production capabilities in Vietnam to meet the increasing requests for its spider silk technology.

Are there any regulatory considerations for KBLB's biomedical applications?

Yes, many biomedical applications of spider silk may require FDA approval.